Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tom Tuschl
Rockefeller University, Department: Genetics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Regulus Therapeutics
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
These grant projects could provide Regulus information about novel biomarkers used for diagnosis of diseases. Regulus' company strategy includes identifying biomarkers.
Clinical utility of extracellular RNA as marker of kidney disease progression
Chronic kidney disease is responsible for enormous human suffering and decreased life expectancy. Identifying patients with greater risk of worsening function of the kidneys may improve their care. We propose to examine urine of patients with kidney disease for the presence of small RNA molecules. We will follow patients to determine whether our approach can identify patients at risk for worsening disease, and will develop a laboratory test that can be used in the clinical setting to manage patients with chronic kidney disease.
Filed on August 23, 2013.
Tell us what you know about Tom Tuschl's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Tom Tuschl”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Tom Tuschl | Rockefeller University | Conflict of Interest | Regulus Therapeutics | $0 - $4,999 |
| Tom Tuschl | Rockefeller University | Conflict of Interest | Regulus Therapeutics | $0 - $4,999 |
| Tom Tuschl | Rockefeller University | Conflict of Interest | Regulus Therapeutics | $20,000 - $39,999 |
| Tom Tuschl | Rockefeller University | Conflict of Interest | Regulus Therapeutics | $100,000 - $149,999 |
| Tom Tuschl | Rockefeller University | Conflict of Interest | Regulus Therapeutics | $20,000 - $39,999 |
| Tom Tuschl | Rockefeller University | Conflict of Interest | Max Planck | $10,000 - $19,999 |
| Tom Tuschl | Rockefeller University | Conflict of Interest | Max Planck | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.